Comments
Jubilant Life Sciences has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc on the prospective Covid-19 drug Remdesivir, for India and other select countries.
In an announcement, Jubilant said its subsidiary Jubilant Generics Ltd has entered into an agreement that will grant it the right to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential therapy for Covid-19, in 127 countries, including India.
These countries consist of nearly all low-income and lower middle-income countries, as well as several upper middle and high-income countries that face significant obstacles to healthcare access, the company said.
Related Stories
Gilead in talks with pharma companies for voluntary licences on remdesivir
Move to address accessibility concerns over antiviral drugUnder the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries.
Shyam S Bhartia, Chairman, and Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences Ltd, said in a statement, “We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s Active Pharmaceutical Ingredient (“API”) in-house helping its cost effectiveness and consistent availability.”
Related Stories
Gilead building ‘a geographically diverse consortium’ to address remdesivir supplies
Recently, patient and health advocacy groups have urged Governments to take such steps and override Gilead’s patents on remdesivir, so other companies would be able to make it at lower prices.Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by USFDA to treat Covid-19. The EUA will facilitate broader use of remdesivir to treat hospitalised patients with severe COVID-19 disease. The EUA is based on available data from two global clinical trials – US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of Covid-19, and Gilead’s global Phase 3 study evaluating remdesivir in patients with severe disease, a note from Jubilant said.
Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of remdesivir as a treatment for Covid-19. Remdesivir remains an investigational drug and has not been approved by the USFDA.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.